Home › Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)
 

Keywords :   


Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)

2016-04-18 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Fourth Designation for KEYTRUDA Follows Breakthrough Status in Advanced Melanoma, Non-Small Cell Lung Cancer, and Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). This is the fourth Breakthrough Therapy Designation granted for KEYTRUDA. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: food administration classical drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.04'Buying a first home is harder when you're single'
27.04This Week in Agribusiness, April 27, 2024
27.04Scentair Adds Patchouli to UK Home Fragrance Offerings
27.04Weekly Recap: Heubach, BASF, PPG Top This Weeks Stories
27.04Commentary: Committed to End Plastic Waste
26.04Dead whistleblower accused Boeing of safety breaches
26.04Introducing Mens Hybrid Skincare Brand Enhanse
26.04Washington Corner April 2024
More »